Results 101 to 110 of about 117,266 (149)

Prognostic Impact of Bone Mineral Density Reduction During Neoadjuvant Chemotherapy (NAC) in Patients Undergoing NAC Followed by Esophagectomy for Esophageal Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
The association between BMD reduction during NAC and the worse prognosis remains unknown, although NAC followed by esophagectomy is a standard treatment for advanced ESCC. This study appeared that BMD massive reduction was an independent prognostic factor on OS (HR, 3.30; 95% confidence interval [CI], 1.69–6.55) and RFS (HR, 2.08; 95% CI, 1.19–3.63 ...
Kazuhide Sato   +11 more
wiley   +1 more source

Influence of Facility Size on Perioperative Outcomes in Minimally Invasive Esophagectomy for 14 152 Patients With Esophageal Cancer Based on the Japanese National Clinical Database: A Multicenter Cohort Study

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This multicenter study investigated 14 152 minimally invasive esophagectomies (MIEs) using data from the Japanese National Clinical Database and showed a significantly lower operative mortality rate in high‐volume centers than in low‐volume centers. However, no differences in morbidity rates were found between facility sizes.
Taro Oshikiri   +4 more
wiley   +1 more source

Survival Outcomes of Esophageal Squamous Cell Carcinoma Patients Who Underwent Salvage Esophagectomy: A Literature Review and Results From Two High‐Volume Centers

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This study aimed to investigate survival outcomes, the efficacy of lymph node (LN) dissection, and recurrence patterns in 69 patients who underwent R0 salvage surgery for esophageal squamous cell carcinoma. Of note, abdominal LN metastases had a negative impact on survival in our series.
Kotaro Sugawara   +9 more
wiley   +1 more source

Long‐Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p 
Takahito Sugase   +19 more
wiley   +1 more source

Leukocyte migration inhibition assay of tumor immunity in patients with cervical squamous cell carcinoma [PDF]

open access: bronze, 1979
Ernesto S. Rivera   +5 more
openalex   +1 more source

Immunostimulatory DNA Tetrahedron‐Based Nanovaccine Combined With Immune Checkpoint PD‐1 Blockade for Boosting Systemic Immune Responses Against Oral Squamous Cell Carcinoma

open access: yesAggregate, EarlyView.
This study introduces an immunomodulatory DNA tetrahedral framework nucleic acid‐based nanovaccine tFNA‐CpG. The functionalized nanovaccine shows stable and well‐defined morphological characteristics and can be efficiently taken up by APCs. When combined with the immune checkpoint inhibitor anti‐PD‐1, it notably ameliorated the immunosuppressive ...
Xueting Yang   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy